Summary of Significant Accounting Policies (Tables)

9 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Customer Information

Significant customer information is as follows:

	December 31,			March 31,
	2022			2022
Percentage of accounts receivable:
Customer B		14	%		0	%
Customer C		70	%		25	%
Customer F		12	%		19	%
Customer G		0	%		44	%

	Three Months Ended December 31,						Nine Months Ended December 31,
	2022			2021			2022			2021
Percentage of revenue:
Customer C		22	%		17	%		20	%		19	%
Customer B		20	%		14	%		18	%		17	%

Summary Of Revenue By Category

The following table presents revenue by category:

	Three Months Ended December 31,										Nine Months Ended December 31,
	2022					2021					2022					2021
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(In thousands, except percentages)
Point in Time
PGS	$	37,499		56	%	$	35,090		62	%	$	117,300		57	%	$	121,516		71	%
Telehealth		8,592		13	%		6,146		11	%		27,124		13	%		6,146		4	%
Consumer services		46,091		69	%		41,236		72	%		144,424		70	%		127,662		75	%
Research services		—		0	%		—		0	%		—		0	%		—		0	%
Total (1)		46,091		69	%		41,236		72	%		144,424		70	%		127,662		75	%
Over Time
PGS		5,100		7	%		3,277		6	%		14,316		7	%		9,189		5	%
Telehealth		2,451		4	%		1,527		3	%		7,471		3	%		1,527		1	%
Consumer services		7,551		11	%		4,804		8	%		21,787		10	%		10,716		6	%
Research services		13,298		20	%		10,851		19	%		40,901		20	%		32,956		19	%
Total (1)		20,849		31	%		15,655		28	%		62,688		30	%		43,672		25	%
Revenue by Category
PGS		42,599		64	%		38,367		67	%		131,616		63	%		130,705		76	%
Telehealth		11,043		16	%		7,673		14	%		34,595		17	%		7,673		5	%
Consumer services		53,642		80	%		46,040		81	%		166,211		80	%		138,378		81	%
Research services		13,298		20	%		10,851		19	%		40,901		20	%		32,956		19	%
Total (1)	$	66,940		100	%	$	56,891		100	%	$	207,112		100	%	$	171,334		100	%

(1)There was no Therapeutics revenue for the three and nine months ended December 31, 2022 and 2021.

Summary of Revenue by Region based on the Shipping Address of Customers

The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered:

	Three Months Ended December 31,										Nine Months Ended December 31,
	2022					2021					2022					2021
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(In thousands, except percentages)
United States	$	46,770		70	%	$	41,741		73	%	$	147,425		71	%	$	120,706		70	%
United Kingdom		16,194		24	%		10,779		19	%		47,198		23	%		37,020		22	%
Canada		2,866		4	%		3,065		6	%		8,744		4	%		9,052		5	%
Other regions		1,110		2	%		1,306		2	%		3,745		2	%		4,556		3	%
Total	$	66,940		100	%	$	56,891		100	%	$	207,112		100	%	$	171,334		100	%

Schedule Of Company Revenue and Adjusted EBITDA by Segment

he Company’s revenue and Adjusted EBITDA by segment is as follows:

	Three Months Ended December 31,						Nine Months Ended December 31,
	2022			2021			2022			2021
	(In thousands)
Segment Revenue:
Consumer and Research Services	$	66,940		$	56,891		$	207,112		$	171,334
Total revenue (1)	$	66,940		$	56,891		$	207,112		$	171,334
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(8,313	)	$	(31,967	)	$	(22,986	)	$	(33,232	)
Therapeutics Adjusted EBITDA		(21,471	)		(19,916	)		(58,599	)		(57,046	)
Unallocated Corporate		(13,488	)		(12,129	)		(41,057	)		(30,692	)
Total Adjusted EBITDA	$	(43,272	)	$	(64,012	)	$	(122,642	)	$	(120,970	)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(91,961	)	$	(89,396	)	$	(247,558	)	$	(147,946	)
Adjustments
Interest (income) expense, net		(3,671	)		(76	)		(5,307	)		(213	)
Other (income) expense, net		(855	)		(22	)		267			(39	)
Change in fair value of warrant liabilities		—			(3,695	)		—			(32,989	)
Income tax benefit		(613	)		(3,512	)		(2,139	)		(3,512	)
Depreciation and amortization		5,257			4,681			15,512			14,188
Amortization of acquired intangible assets		4,265			2,898			12,847			2,898
Impairment of acquired intangible assets		9,968			—			9,968			—
Stock-based compensation expense		34,338			17,409			93,768			37,473
Acquisition-related costs (2)		—			7,701			—			9,170
Total Adjusted EBITDA	$	(43,272	)	$	(64,012	)	$	(122,642	)	$	(120,970	)

(1)There was no Therapeutics revenue for the three and nine months ended December 31, 2022 and 2021.

(2)For the three and nine months ended December 31, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees.

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:

	Three Months Ended December 31,								Nine Months Ended December 31,
	2022				2021				2022				2021
	(In thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C (1)	$	14,680	22	%	$	9,676	17	%	$	41,365	20	%	$	33,123	19	%
Customer B (2)	$	13,068	20	%	$	8,069	14	%	$	36,258	18	%	$	29,281	17	%

(1)Customer C revenues are primarily in the United States.

(2)Customer B revenues are in the U.K.